No Data
Hong Kong stock market volatility | Ke D-B (02487) rose more than 5% in early trading, pipeline progress exceeded expectations, institutions said next year is a key business year for the company.
Ke Di-B (02487) rose more than 5% in early trading. As of the time of publication, it has risen 3.87%, at a price of HK$12.34, with a turnover of HK$2.3564 million.
CUTIA-B: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2023 ANNUAL REPORT
CICC: Reaffirmed the "outperform" rating for Sea Ltd (02487), with the target price raised to HK$15.2.
CLSA expects Kadi will launch three core products, CU-40102, CU-10201, and CU-30101, over the next 12 months.
Keystone Corporation B (02487.HK): The first half of the year's earnings increased by 178.3% year-on-year to 95.6 million yuan.
Collins August 29th. Koddi-B (02487.HK) announced that for the six months ended June 30, 2024, the income increased by about 178.3% compared to the previous year, reaching approximately RMB 95.6 million; the gross margin increased by about 5 percentage points from around 48% for the six months ended December 31, 2023, to around 53% for the six months ended June 30, 2024. For the six months ended June 30, 2024, the adjusted net loss was approximately RMB 0.161 billion (non-International Financial Reporting Standards adjustment). The group continues to optimize its operating efficiency, with the adjusted net loss as a proportion of income.
Keidi-B (02487) released its interim performance, with a shareholder net loss of 0.201 billion yuan, a year-on-year decrease of 87.75%.
Kedi-B (02487) released its interim performance for the six months ending on June 30, 2024, and the group achieved revenue...
Express News | Cutia Therapeutics - Loss of RMB200.9 Mln for Six Months
No Data
